Presentation Date
13-10-2022 12:00 AM
Description
INTRODUCTION: Studies have shown that vulvar cancer and dysplasia progression is often related to human papillomavirus (HPV) or other conditions. It has been suggested that patients with HPV-related vulvar cancer or dysplasia are likely to have died from a comorbidity rather than from vulvar disease, while patients with vulvar cancer or dysplasia unrelated to HPV often present with more aggressive forms of vulvar disease. The objective of this study was to describe the causes of death in Louisiana patients with vulvar cancer or dysplasia. METHODS: Retrospective analysis of 53 Louisiana patients diagnosed with vulvar cancer or dysplasia between 2013 and 2022 was performed. Patients were seen at a mix of academic and community hospitals. Patient data was abstracted for demographic and clinical variables including tobacco history, HPV status, comorbidities, and disease status. Categorical distributions across groups were analyzed using Fisher exact tests and two-sample t-tests, and continuous covariates were summarized using a Wilcoxon rank-sum test. RESULTS: Of the 35 patients with vulvar cancer and 18 patients with vulvar dysplasia, 31 patients (58.5%) were alive without disease, 18 (34.0%) alive with disease, 3 (5.7%) dead of unreported causes, and 1 (1.9%) dead of vulvar cancer. The average age of patients with advanced vulvar cancer (62.4 years) was greater than those with early-stage vulvar cancer (56.2 years) or dysplasia (51.2 years), though this was not significant (p=.26). While insignificant, there was a higher rate of HPV in patients with vulvar cancer (p=1.0). While patients with early-stage vulvar cancer tended to show higher rates of HPV than patients with late-stage vulvar cancer, this was also not significant (n=12 vs. n=3, p=.70). The average Charlson Comorbidity Index (CCI) score of vulvar cancer patients was significantly greater than patients with vulvar dysplasia (4.89 vs. 2.44, p
Recommended Citation
Khan, Yaseen; Bardarson, Amber R.; Dunbar, Afryea L.; Keller, Madison A.; Jernigan, Amelia; Chapple, Andrew; Nair, Navya; and Castellano, Tara, "Demographic and Clinical Insight into the Comorbidities and Mortality of Patients with Vulvar Cancer or Dysplasia in Louisiana" (2022). Medical Student Research Poster Symposium. 96.
https://digitalscholar.lsuhsc.edu/sommrd/2022MRD/Posters/96
Included in
Demographic and Clinical Insight into the Comorbidities and Mortality of Patients with Vulvar Cancer or Dysplasia in Louisiana
INTRODUCTION: Studies have shown that vulvar cancer and dysplasia progression is often related to human papillomavirus (HPV) or other conditions. It has been suggested that patients with HPV-related vulvar cancer or dysplasia are likely to have died from a comorbidity rather than from vulvar disease, while patients with vulvar cancer or dysplasia unrelated to HPV often present with more aggressive forms of vulvar disease. The objective of this study was to describe the causes of death in Louisiana patients with vulvar cancer or dysplasia. METHODS: Retrospective analysis of 53 Louisiana patients diagnosed with vulvar cancer or dysplasia between 2013 and 2022 was performed. Patients were seen at a mix of academic and community hospitals. Patient data was abstracted for demographic and clinical variables including tobacco history, HPV status, comorbidities, and disease status. Categorical distributions across groups were analyzed using Fisher exact tests and two-sample t-tests, and continuous covariates were summarized using a Wilcoxon rank-sum test. RESULTS: Of the 35 patients with vulvar cancer and 18 patients with vulvar dysplasia, 31 patients (58.5%) were alive without disease, 18 (34.0%) alive with disease, 3 (5.7%) dead of unreported causes, and 1 (1.9%) dead of vulvar cancer. The average age of patients with advanced vulvar cancer (62.4 years) was greater than those with early-stage vulvar cancer (56.2 years) or dysplasia (51.2 years), though this was not significant (p=.26). While insignificant, there was a higher rate of HPV in patients with vulvar cancer (p=1.0). While patients with early-stage vulvar cancer tended to show higher rates of HPV than patients with late-stage vulvar cancer, this was also not significant (n=12 vs. n=3, p=.70). The average Charlson Comorbidity Index (CCI) score of vulvar cancer patients was significantly greater than patients with vulvar dysplasia (4.89 vs. 2.44, p
Comments
IN COPYRIGHT. For more information about this rights statement, please visit http://rightsstatements.org/vocab/InC/1.0/